03.12.2015 Views

bbc 2015

BBC2015_booklet

BBC2015_booklet

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

BeNeLux Bioinformatics Conference – Antwerp, December 7-8 <strong>2015</strong><br />

Abstract ID: P<br />

Poster<br />

10th Benelux Bioinformatics Conference <strong>bbc</strong> <strong>2015</strong><br />

P43. BINDING SITE SIMILARITY DRUG REPOSITIONING:<br />

A GENERAL AND SYSTEMATIC METHOD FOR DRUG DISCOVERY<br />

AND SIDE EFFECTS DETECTION<br />

Daniele Parisi & Yves Moreau.<br />

I developed a protocol based on prediction of druggable cavities, comparison of these putative binding sites and crossdocking<br />

between bound ligands and the binding site detected to be similar to the one of the complex, in order to study the<br />

cross reactivity of known compounds. It is a general method because it can find applications both in drug repositioning<br />

and in the study of adverse effects, and it is systematic because it consists in several subsequent steps. It would indicate<br />

ligands to screen, reducing the number of candidates and allowing companies or universities to save money and time<br />

from unnecessary tests.<br />

INTRODUCTION<br />

The ability of small molecules to interact with multiple<br />

proteins is referred to as polypharmacology [1] , and the<br />

strategy that aims to exploit the positive aspects of<br />

polypharmacology is drug repositioning, whereby existing<br />

drugs are investigated for efficacy against targets for other<br />

indications. Existing drugs are privileged structures with<br />

verified bioavailability and compatibility. Furthermore,<br />

virtual screening allows to conduct repositioning of<br />

existing drugs against novel disease targets without the<br />

expense of purchasing thousands of compounds [2] . The<br />

combination of structure-based virtual screening (such as<br />

estimation of similarity of protein-ligand binding sites and<br />

consequent cross-docking) and drug repositioning<br />

represents a highly efficient and fast methodology for<br />

predicting cross-reactivity and putative side effects of drug<br />

candidates [3] .<br />

METHODS<br />

Each step of my work is related to a bioinformatics<br />

technique or tool, resulting to be the coupling of different<br />

software.<br />

1. At first there is the choice of the query (a single protein<br />

as PDB file) and the templates (a set of PDB<br />

structures). At least one of the two categories has to<br />

present a ligand bound in a cavity;<br />

2. prediction of druggable cavities in all the protein<br />

structures using a geometry-based or an energy-based<br />

algorithm (Fpocket, geometry-based tool, in my case);<br />

3. comparison of the query binding sites to the binding<br />

sites of the templates for assessing the similarity. It can<br />

be carried out by an alignment or alignment-free<br />

algorithm (I used Apoc, an alignment based tool);<br />

4. cross-docking of the ligand available in the pair of<br />

similar binding sites, into the other cavity, in order to<br />

study the binding with a different target for toxicity or<br />

new therapeutic indications (AutodockVina);<br />

5. Fingerprinting of the new complex ligand-cavity for<br />

scoring the docking poses.<br />

I applied this protocol on two different queries (Thrombin<br />

and Dihydrofolate reductase), using a data set of 1067<br />

druggable proteins as tamplates (Druggable Cavity<br />

Directory).<br />

RESULTS & DISCUSSION<br />

The method works well in repositioning ligands among<br />

proteins of the same family (intraprotein), but is not able<br />

to detect interprotein similarities (among not related<br />

proteins). It happens because of the big size of the<br />

predicted cavities (larger than the mere space occupied by<br />

the ligand) coupled to the alignment-based algorithm used,<br />

which make difficult to have a sufficient similarity rate<br />

and exponentially increase the false negatives. For my<br />

further works I will divide the cavity space in subpockets,<br />

disengage the similarity from the sequence by using<br />

pharmacophoric maps, and couple the structure based<br />

similarity to the ligand based and network based. All the<br />

information will be fused with data integrations algorithms.<br />

REFERENCES<br />

On the origins of drug polypharmacology, Xavier Jalencas and Jordi<br />

Mestres, Med. Chem. Commun., 2013, 4, 80.<br />

Drug repositioning by structure-based virtual screening, Dik-Lung Ma,<br />

Daniel Shiu-Hin Chana and Chung-Hang Leung, Chem. Soc. Rev.,<br />

2013, 42, 2130.<br />

Comparison and Druggability Prediction of Protein−Ligand Binding<br />

Sites from Pharmacophore-Annotated Cavity Shapes, Jérémy<br />

Desaphy, Karima Azdimousa, Esther Kellenberger, and Didier<br />

Rognan, J. Chem. Inf. Model. 2012, 52, 2287−2299.<br />

87

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!